Lixte Biotechnology (NASDAQ:LIXT) Posts Earnings Results

Lixte Biotechnology (NASDAQ:LIXT) announced its quarterly earnings data on Monday. The company reported ($0.27) earnings per share for the quarter, Zacks reports.

Lixte Biotechnology Stock Performance

NASDAQ LIXT traded down $0.02 on Monday, reaching $1.29. 17,957 shares of the company’s stock traded hands, compared to its average volume of 317,816. The firm has a market cap of $2.90 million, a price-to-earnings ratio of -0.75 and a beta of 0.19. The stock has a 50 day moving average price of $1.81 and a 200-day moving average price of $1.89. Lixte Biotechnology has a fifty-two week low of $1.02 and a fifty-two week high of $4.40.

Lixte Biotechnology Company Profile

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.